Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Oh

Showing results (531-540 of 552) with videos related to

Pageof 56
Sort By:
JCO Precision Oncology|May 26, 2021
Impact of a 40-Gene Targeted Panel Test on Physician Decision Making for Patients With Acute Myeloid LeukemiaErica K Barnell, Kenneth F Newcomer, Zachary L Skidmore, et al.
Nature Medicine|March 11, 2025
Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trialRaajit K Rampal, Sebastian Grosicki, Dominik Chraniuk, et al.
Leukemia|October 4, 2024
Monitoring clonal burden as an alternative to blast count for myelodysplastic neoplasm treatment responseMeagan A Jacoby, Eric D Duncavage, Ajay Khanna, et al.
Frontiers in Medicine|May 7, 2025
A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in patients with essential thrombocythemia in the US and Canada: EXCEED-ET trialLucia Masarova, Brandi N Reeves, Firas El Chaer, et al.
Lancet Regional Health. Americas|June 17, 2026
Ropeginterferon alfa-2b-njft treatment in essential thrombocythemia across different driver mutations: results from a North American, single-arm, multicentre study (EXCEED-ET)Brandi N Reeves, Firas El Chaer, Lynda Foltz, et al.
The Lancet. Haematology|November 5, 2025
Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 studyRuben Mesa, Harinder Gill, Lei Zhang, et al.
Retina (Philadelphia, Pa.)|October 20, 2020
CLINICAL OUTCOMES AND TREATMENT COURSE OF EYES WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION FOLLOWING THE DEVELOPMENT OF ENDOPHTHALMITISNicole Koulisis, Stavros N Moysidis, Viren K Govindaraju, et al.
Nature Communications|January 27, 2026
Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer: a phase 2 trialTim Kong, Alex Mabry, Maureen Highkin, et al.
Nature Communications|May 8, 2021
Co-evolution of tumor and immune cells during progression of multiple myelomaRuiyang Liu, Qingsong Gao, Steven M Foltz, et al.
Blood|August 2, 2019
Genomic landscape of neutrophilic leukemias of ambiguous diagnosisHaijiao Zhang, Beth Wilmot, Daniel Bottomly, et al.
Pageof 56

Showing results (531-540 of 552) with videos related to

Sort By:
Pageof 56
JCO Precision Oncology|May 26, 2021
Impact of a 40-Gene Targeted Panel Test on Physician Decision Making for Patients With Acute Myeloid LeukemiaErica K Barnell, Kenneth F Newcomer, Zachary L Skidmore, et al.
Nature Medicine|March 11, 2025
Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trialRaajit K Rampal, Sebastian Grosicki, Dominik Chraniuk, et al.
Leukemia|October 4, 2024
Monitoring clonal burden as an alternative to blast count for myelodysplastic neoplasm treatment responseMeagan A Jacoby, Eric D Duncavage, Ajay Khanna, et al.
Frontiers in Medicine|May 7, 2025
A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in patients with essential thrombocythemia in the US and Canada: EXCEED-ET trialLucia Masarova, Brandi N Reeves, Firas El Chaer, et al.
Lancet Regional Health. Americas|June 17, 2026
Ropeginterferon alfa-2b-njft treatment in essential thrombocythemia across different driver mutations: results from a North American, single-arm, multicentre study (EXCEED-ET)Brandi N Reeves, Firas El Chaer, Lynda Foltz, et al.
The Lancet. Haematology|November 5, 2025
Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 studyRuben Mesa, Harinder Gill, Lei Zhang, et al.
Retina (Philadelphia, Pa.)|October 20, 2020
CLINICAL OUTCOMES AND TREATMENT COURSE OF EYES WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION FOLLOWING THE DEVELOPMENT OF ENDOPHTHALMITISNicole Koulisis, Stavros N Moysidis, Viren K Govindaraju, et al.
Nature Communications|January 27, 2026
Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer: a phase 2 trialTim Kong, Alex Mabry, Maureen Highkin, et al.
Nature Communications|May 8, 2021
Co-evolution of tumor and immune cells during progression of multiple myelomaRuiyang Liu, Qingsong Gao, Steven M Foltz, et al.
Blood|August 2, 2019
Genomic landscape of neutrophilic leukemias of ambiguous diagnosisHaijiao Zhang, Beth Wilmot, Daniel Bottomly, et al.
Pageof 56